AVCO / Avalon GloboCare reveals new study using AI-powered protein design technology targeting glucose transporter against cancer

Avalon GloboCare Corp (NASDAQ:ALBT) has encouraged its shareholders to vote on a number of key proposals at its upcoming annual meeting to be held o more_horizontal

Avalon GloboCare Corp (NASDAQ:AVCO) announced a new study incorporating artificial intelligence (AI)-enhanced protein design technology that could acc more_horizontal

Avalon GloboCare Corp (NASDAQ:AVCO) has signed a memorandum of understanding with Lu Daopei Hematology Institute (LDHI) to co-develop precision compan more_horizontal

Avalon GloboCare Corp (NASDAQ: AVCO) is expanding its cellular immuno-oncology program with the addition of novel Chimeric Antigen Receptor – Natu more_horizontal

Avalon GloboCare Corp (NASDAQ: AVCO) is expanding its cellular immuno-oncology program with the addition of novel Chimeric Antigen Receptor – Natu more_horizontal

Avalon GloboCare Corp (NASDAQ: AVCO) is expanding its cellular immuno-oncology program with the addition of novel Chimeric Antigen Receptor – Natu more_horizontal

Avalon GloboCare Corp (NASDAQ:AVCO) said it is expanding its cellular immuno-oncology program with the addition of novel Chimeric Antigen Receptor-Nat more_horizontal

Avalon GloboCare Corp (NASDAQ:AVCO) said it is expanding its cellular immuno-oncology program with the addition of novel Chimeric Antigen Receptor-Nat more_horizontal